

Contact:

Douglas Kolodny-Hirsch, Ph.D., M.B.A.
Senior Director, Business Development
MaxCyte, Inc.
(301) 944-1700

For Immediate Release

MaxCyte To Present at Bio Korea, BioJapan and Global Venture Forum Japan

Gaithersburg, MD, August 23, 2006 – MaxCyte, Inc., a clinical stage therapeutic company and pioneer in clinical scale, non-viral cell loading systems, announced today that Douglas Kolodny-Hirsch, Ph.D., Senior Director Business Development, will be presenting at the Bio Korea 2006 Conference in Seoul, Coex Conference Center, on September 6 - 8, 2006, and at the BioJapan World Business Forum 2006 and the Global Venture Forum 2006 in Osaka's International Convention Center, which are being held September 13 – 15, 2006.

Dr. Kolodny-Hirsch will provide a corporate overview and discuss the company's preclinical and clinical product candidates, enabling technology for therapeutic development and biotherapeutic manufacturing and partnering activities.

About MaxCyte

MaxCyte Inc. is a clinical stage company developing cell-based therapeutics primarily in the areas of oncology and regenerative medicine. MaxCyte's pipeline includes one product in Phase I/II clinical trials for the treatment of Chronic Lymphocytic Leukemia (CLL) and several preclinical candidates to treat a variety of diseases with unmet needs. The company also offers its unparalleled, customizable flow based cell loading technology to partners who take advantage of its advanced capabilities for cell-based therapeutic development and biotherapeutic (viral vector) manufacturing through licensing relationships. Partners are currently working to develop therapeutics for pulmonary, cardiovascular and infectious disease, cancer and regenerative medicine.

For more information, visit <http://www.maxcyte.com>.

This press release may contain, in addition to historical information, certain forward-looking statements that involve risks and uncertainties. Such statements reflect management's current views and are based on certain assumptions. Actual results could differ materially from those currently anticipated as a result of a number of factors, including risks and uncertainties.

###